Trend of salvage treatment in diffuse large B cell lymphoma in the outpatient chemotherapy era
- Authors:
- Published online on: October 3, 2019 https://doi.org/10.3892/mco.2019.1930
- Pages: 557-562
-
Copyright: © Nakaya et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Patients with diffuse large B cell lymphoma (DLBCL) who have failed to achieve complete remission with first‑line therapy can subsequently receive salvage therapy. However, there is no definite consensus on the use of salvage therapy, and little information on the optimal treatment regimen. The present study retrospectively analyzed data from 131 patients diagnosed with DLBCL between April 2002 and November 2017 who relapsed and received salvage therapy. Primary treatment included R‑CHOP or R‑CHOP‑like regimens. The most common salvage regimen was R‑DeVIC (42%), followed by R‑ESHAP (23%), other aggressive regimens (12%) and palliative therapy (23%). The median overall survival (OS) was 45.7 months for R‑DeVIC, 41.8 months for palliative therapy, 29.4 months for R‑ESHAP, and 28.5 months for aggressive regimens (P=0.937). A total of 25 patients underwent autologous stem cell transplantation (ASCT), and the OS was 75.6 months for these patients compared with 33.5 months (range, 25.6‑45.6 months) for patients who did not undergo ASCT (P=0.033). Following the establishment of an outpatient chemotherapy unit in 2014, R‑DeVIC use became more common, increasing from 37% prior to 2014 to 46% after 2014, whereas R‑ESHAP use decreased (31 to 17%). The present study did not identify the optimal salvage regimen for patients with DLBCL. However, salvage ASCT improved the outcome, and regimens administered via peripheral veins were demonstrated to be more common in outpatient chemotherapy settings.
